ClinicalTrials.Veeva

Menu

Rhomboid Intercostal Plane Block vs Local Anesthetic Infilteration for Postoperative Analgesia After Thoracoscopic Surgery

A

Ain Shams University

Status

Unknown

Conditions

Anesthesia

Treatments

Other: Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine

Study type

Interventional

Funder types

Other

Identifiers

NCT04821947
FMASU R 34/2021

Details and patient eligibility

About

The purpose of the study is to evaluatethe effects of rhomboid intercostal block( RIB ) on postoperative pain after thoracoscopic surgery compared with local anesthetic infiltration ( LA )

Enrollment

60 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ASA status I &II

Exclusion criteria

  • Allergic constitution
  • Severe cardiovascular or hepatorenal insufficiency
  • Coagulation system disease
  • Injection site infection
  • Morbid obesity (BMI>40 kg/m2).

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

60 participants in 2 patient groups

RIB Group
Active Comparator group
Description:
Drug: Bupivacaine 0.25% patients will receive 20 ml of bupivacaine 0.25% in the rhomboid plane under rhomboid major muscle
Treatment:
Other: Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine
LA Group
Active Comparator group
Description:
Drug: Bupivacaine 0.25% patients will receive wound infiltration of VATS incision, single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine .
Treatment:
Other: Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine

Trial contacts and locations

0

Loading...

Central trial contact

Heba Fouad, MD; Rehab Abdelfattah, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems